Patients & Caregivers
Follicular Lymphoma Treatment Gets FDA Priority Review
The FDA has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for follicular lymphoma treatment Gazyva (obinutuzumab).
Mycosis Fungoides and Sezary Syndrome Treatment Gets Breakthrough Therapy Designation
Breakthrough Therapy Designation status was granted to mogamulizumab to treat subtytes of cutaneous T-cell lymphoma – mycosis fungoisis and Sézary syndrome.
Patriots Fan Gets Wishes Granted While Undergoing Chemotherapy
Bucket list items: 1) survive cancer; 2) meet Tom Brady; 3) attend Patriots game
Afinitor Effective in Neuroendocrine Tumors; Quality of Life Scores Not Significantly Improved
In February 2016, the FDA approved Afinitor (everolimus) for treating neuroendocrine tumors (NETs) of gastrointestinal or lung origin.
J&J Told to Pay Ovarian Cancer Patient $417 Million
The verdict included $70 million in compensatory damages and $347 million in punitive damages.
Targeted AML Treatment Gets FDA Orphan Drug Designation
Syros announced that the U.S. FDA has granted orphan drug designation to its leading drug candidate SY-1425, intended to treat acute myeloid leukemia (AML).
Blastic Plasmacytoid Dendritic Neoplasm Study Begins for CAR T-Cell Candidate
A Phase 1 clinical study testing CAR T-cell therapy, UCART123,to treat blastic plasmacytoid dendritic cell neoplasm at the MD Anderson Cancer Center has begun.
Glioblastoma Treatment Gets FDA Orphan Drug Designation
Curtana announced the FDA has granted CT-179 with an Orphan Drug Designation to treat for gliomas, including glioblastoma in adults and brain tumors in children.
FDA Approves Ovarian Cancer Treatment
The FDA approved olaparib tablets (Lynparza) for adult patients with recurrent epithelial ovarian fallopian tube, or primary peritoneal cancer.
FDA Approves Pfizer Drug for Acute Lymphoblastic Leukemia
FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor ALL
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.